PF-4708671

For research use only. Not for use in humans.

Pfizer辉瑞授权生产 目录号：S2163

PF-4708671 Chemical Structure

CAS No. 1255517-76-0

PF-4708671是一种细胞渗透性p70 ribosomal S6 kinase(S6K1亚型)抑制剂，在无细胞试验中Ki/IC50为20 nM/160 nM，作用于S6K1比作用于S6K2选择性高400倍，作用于S6K1比作用于MSK1和RSK1/2选择性分别高4和20倍以上，是第一个报道的S6K1特异性抑制剂。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1574.66 现货
RMB 876.33 现货
RMB 1179.06 现货
RMB 2197.72 现货
有超大折扣
大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck生产的PF-4708671发表文献36篇：

产品安全说明书

S6 Kinase抑制剂选择性比较

生物活性

产品描述 PF-4708671是一种细胞渗透性p70 ribosomal S6 kinase(S6K1亚型)抑制剂，在无细胞试验中Ki/IC50为20 nM/160 nM，作用于S6K1比作用于S6K2选择性高400倍，作用于S6K1比作用于MSK1和RSK1/2选择性分别高4和20倍以上，是第一个报道的S6K1特异性抑制剂。
靶点
p70 S6K1 [1]
(Cell-free assay)
160 nM
体外研究

PF-4708671是一种哌嗪基嘧啶类似物，是第一个S6K1特异性抑制剂。PF-4708671不显著抑制紧密相关的S6K2亚型或一组其他AGC激酶 (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 或SGK1)的活性。PF-4708671抑制S6K1介导的响应IGF-1（胰岛素样生长因子1）的S6蛋白的磷酸化，对PMA-诱导的底物磷酸化没有作用效果，底物与RSK (p90核糖体S6激酶)和MSK（丝分裂原和应激活化蛋白激酶）激酶高度相关。PF-4708671诱导S6K1的T型环和疏水性基序磷酸化，这种作用依赖于mTORC1 (mTOR复合体1)。PF-4708671不影响mTORC1的活性。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BHT-101 M{my[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwOEKwNlQh|ryP NFTlV4JUSU6JRWK=
UACC-893 Mk\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LNbGlEPTB;NT6xPVg5PiEQvF2= M135eHNCVkeHUh?=
A427 M4r5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rEVGlEPTB;NT63NlU3PyEQvF2= MVnTRW5ITVJ?
OCUB-M MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TQNWlEPTB;Nj62OlExOiEQvF2= MkKxV2FPT0WU
SW684 NHXlOnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTdwNUKyOlgh|ryP NEjFV25USU6JRWK=
SK-LMS-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFqzNpRKSzVyPUmuNFE{ODJizszN MknlV2FPT0WU
CP50-MEL-B M4X4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnkT|hFUUN3ME25MlMxPDF7IN88US=> MVTTRW5ITVJ?
NCI-H1651 NYXJfnROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3OTWM2OD1zMD6wNlc3KM7:TR?= NF3TcmtUSU6JRWK=
ABC-1 Mn[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEC1eVNKSzVyPUGwMlExOzdizszN MW\TRW5ITVJ?
OE19 MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nKV2lEPTB;MUCuNVc{OyEQvF2= MWDTRW5ITVJ?
DSH1 M324eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHjVY9WUUN3ME2xNE45QDd7IN88US=> MlS3V2FPT0WU
SW13 MmnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTFzLkmzNVkh|ryP MniwV2FPT0WU
MDA-MB-453 Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7aO4hxUUN3ME2xNk4yPjB|IN88US=> MkjQV2FPT0WU
647-V MlTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfpTWM2OD1zMj6zOVgzKM7:TR?= MoD3V2FPT0WU
NCI-H2342 M4[x[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2[2OmlEPTB;MUKuN|k6PSEQvF2= NYGz[GgyW0GQR1XS
LB2241-RCC M4TzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGi2OJpKSzVyPUGyMlU4PzlizszN MWDTRW5ITVJ?
UACC-257 NEjYfWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTF|LkS0OVMh|ryP NGm4ToJUSU6JRWK=
NCI-H661 NFKxNo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTvTWM2OD1zMz62OFQ6KM7:TR?= NIPxeJJUSU6JRWK=
FADU NFjwTI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTF|Lk[5PVIh|ryP NIXJOo9USU6JRWK=
A2780 MkDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvpZo0{UUN3ME2xN{45ODRzIN88US=> MkThV2FPT0WU
NCI-H1793 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzETWM2OD1zND60NFg2KM7:TR?= Mm[xV2FPT0WU
TE-8 MlnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnUd4hKSzVyPUG1MlM1PjVizszN MWPTRW5ITVJ?
HGC-27 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7STWM2OD1zNj6xOlQ1KM7:TR?= MoPYV2FPT0WU
MMAC-SF Mlv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTF5LkO3Nlch|ryP NF;NdppUSU6JRWK=
Calu-6 NWTidnAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzWTWM2OD1zOD6xOVE{KM7:TR?= MlfrV2FPT0WU
HUTU-80 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnmXpJKSzVyPUG4MlM6PTlizszN NGXBXFZUSU6JRWK=
SAS MnXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzZboVKUUN3ME2xPE43PDV3IN88US=> M2[yXnNCVkeHUh?=
IST-MES1 M2jBR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml74TWM2OD1zOD62OVA5KM7:TR?= M2D5T3NCVkeHUh?=
C3A MknPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTF6Lke5NVkh|ryP NEnrTXRUSU6JRWK=
ES3 NYjOUIZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLBe|ZKSzVyPUG4Mlg{PjRizszN NILJOnBUSU6JRWK=
HSC-2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnNWoRWUUN3ME2xPU43PTRzIN88US=> NHnVOXBUSU6JRWK=
T47D M3v5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjYRotQUUN3ME2yNE4yPDh3IN88US=> NH\VfW1USU6JRWK=
EW-7 NHLaXWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;P[2hbUUN3ME2yNE45PTh6IN88US=> NWroZ|FnW0GQR1XS
LN-405 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vO[GlEPTB;MkCuPFk3PSEQvF2= MlfIV2FPT0WU
U031 NHKyTY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDwXpd{UUN3ME2yNU41QDB{IN88US=> NGX4PYpUSU6JRWK=
A549 NV3CXVNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJzLki0PVEh|ryP MX3TRW5ITVJ?
RMG-I M3zlPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrpTWM2OD1{Mj6yOlY5KM7:TR?= NXLrV40{W0GQR1XS
BT-474 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4W5fmlEPTB;MkKuOlU2OSEQvF2= M{LVPHNCVkeHUh?=
NB69 M37YR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1e5c2lEPTB;MkOuNVUzKM7:TR?= NFu2W3pUSU6JRWK=
NB7 NWK4eZh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjkTWM2OD1{ND6xPFgh|ryP NWHjXXEyW0GQR1XS
HCC1569 M4fFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTJ2Lk[xNlUh|ryP MnLCV2FPT0WU
MEL-JUSO NH7MSGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\vSGtIUUN3ME2yOE43QTB6IN88US=> NWLQd3NxW0GQR1XS
MDA-MB-175-VII NVnjRXJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1z2[WlEPTB;MkWuNlUyPyEQvF2= M3;3dXNCVkeHUh?=
HCC1419 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHjTWM2OD1{NT62NFA{KM7:TR?= MUXTRW5ITVJ?
Ca9-22 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{n2cWlEPTB;MkWuOlQ{OiEQvF2= M4e1enNCVkeHUh?=
KGN NX[1TWRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjm[G57UUN3ME2yOU44PTR5IN88US=> NG\QU3pUSU6JRWK=
LB373-MEL-D MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nNdWlEPTB;Mk[uNVk{QCEQvF2= NEfMTGdUSU6JRWK=
NCI-H1755 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvvTWM2OD1{Nj64PFQyKM7:TR?= NI\KWGhUSU6JRWK=
D-423MG M4XZfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2r0OGlEPTB;MkeuNFcyPSEQvF2= MkTDV2FPT0WU
DK-MG MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW1TWM2OD1{OD63PFQ3KM7:TR?= MnnEV2FPT0WU
NCI-H1623 M2m1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjyTWM2OD1{OD64N|QzKM7:TR?= M1zQNXNCVkeHUh?=
KU-19-19 Mk\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nwV2lEPTB;MkiuPVk2KM7:TR?= NHOxOpZUSU6JRWK=
C-33-A M36weWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7JVYRKSzVyPUK5MlIyQThizszN NV33TGdVW0GQR1XS
SCC-4 MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7PTWM2OD1|MD6zN|U1KM7:TR?= MUPTRW5ITVJ?
MG-63 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXqTWM2OD1|MD61PVk1KM7:TR?= MX;TRW5ITVJ?
LNCaP-Clone-FGC NIjhWHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTLbJhKSzVyPUOxMlQ6OjFizszN NILTTWdUSU6JRWK=
CAPAN-1 MnTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHuTJpKSzVyPUOxMlUzQDZizszN M1:1XnNCVkeHUh?=
GI-ME-N NYX5XJdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHq2O5NKSzVyPUOxMlU{PTNizszN NFXkR3RUSU6JRWK=
RERF-LC-MS Mlj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHH0W|dKSzVyPUOyMlY4PDdizszN M4\3NnNCVkeHUh?=
KLE NEjPWXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFr0PVFKSzVyPUOzMlQ{OzRizszN NFLFN|JUSU6JRWK=
KNS-81-FD M2Lnbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTN|LkWwNFgh|ryP NWfa[2ZRW0GQR1XS
DOK M1;ISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTN2Lk[2NVIh|ryP NWexdmdQW0GQR1XS
ACHN NFP5bmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rYWmlEPTB;M{WuNVU5QCEQvF2= NFPBXoZUSU6JRWK=
KYSE-520 M17q[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjMOm9KSzVyPUO1MlI{PjFizszN NUjVPIZ[W0GQR1XS
SBC-5 NVHXW3NnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTN3LkWxNVYh|ryP M4GyfXNCVkeHUh?=
NCI-H28 M3;s[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLYTWM2OD1|NT62Olk2KM7:TR?= NGPyU5JUSU6JRWK=
ES7 NEXmVmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHJVnJ[UUN3ME2zOk4zOjR7IN88US=> NGPsRolUSU6JRWK=
A172 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzlTWM2OD1|Nj60NVg4KM7:TR?= NWLrWFFiW0GQR1XS
UM-UC-3 M2Pndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXlV4dCUUN3ME2zO{45PzR4IN88US=> NH;zcWdUSU6JRWK=
LXF-289 NU\oSIc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrSPIlxUUN3ME2zPE4xODR5IN88US=> NXPqfIRkW0GQR1XS
KP-4 NEL6UYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLCTWM2OD1|OD60O|M6KM7:TR?= NEWxZ|BUSU6JRWK=
TE-1 NHTPTmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfWTWM2OD1|OT62OVg6KM7:TR?= MlP1V2FPT0WU
G-402 NHPQWZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzxTWM2OD12MD6wOlEh|ryP M{KwO3NCVkeHUh?=
786-0 NVG2T3VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILHPYlKSzVyPUSwMlkxQTZizszN MWXTRW5ITVJ?
K5 MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXIU4ZKSzVyPUSxMlM3QDZizszN NVPqW3pvW0GQR1XS
SK-N-DZ NGjaUWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ntc2lEPTB;NEGuN|gzOyEQvF2= MoLSV2FPT0WU
OVCAR-4 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTRzLke1Olgh|ryP NXzxZ3plW0GQR1XS
T84 NGLFOG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37ud2lEPTB;NEKuNVI3OyEQvF2= M3rDNXNCVkeHUh?=
GCIY MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHVUoNKSzVyPUSzMlA5ODNizszN NEfVSGpUSU6JRWK=
BB49-HNC M1jYUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPiXmduUUN3ME20N{4{OzR6IN88US=> MoHuV2FPT0WU
SNU-C2B MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTSTWM2OD12Mz62OFM3KM7:TR?= NUH2OlE3W0GQR1XS
TE-6 NUe4RY5ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moq4TWM2OD12Mz64PFk1KM7:TR?= NHW0[XFUSU6JRWK=
23132-87 M1jWdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPXcJlKSzVyPUS0MlI6PzhizszN NVHtcHRvW0GQR1XS
DMS-53 NGT2WVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrSOI5KSzVyPUS0MlM{QDRizszN M4nJfXNCVkeHUh?=
ONS-76 NHq3cXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWD5dmlGUUN3ME20OE44PjZzIN88US=> M2LTU3NCVkeHUh?=
DMS-273 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrBTWM2OD12ND65OFMh|ryP MULTRW5ITVJ?
COLO-824 M3PCOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rGWWlEPTB;NEWuPFc4PSEQvF2= MoLJV2FPT0WU
DMS-114 M4jkPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTR3Lki5Nlch|ryP MlW4V2FPT0WU
YKG-1 M4TmNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTBTWM2OD12Nj6wN|U2KM7:TR?= MnmxV2FPT0WU
RH-18 M{XGd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLYUGh4UUN3ME20Ok4{PzN|IN88US=> Mn\kV2FPT0WU
NCI-H1355 M3Xtdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nTSWlEPTB;NE[uOlE5KM7:TR?= NVXke3BvW0GQR1XS
NCI-H2170 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnCRW9KSzVyPUS3Mlc2QDRizszN MlfrV2FPT0WU
OC-314 M3jqbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DsdWlEPTB;NEeuPFQ4QCEQvF2= NWTBV2hwW0GQR1XS
NCI-H2030 MnvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTR5Lki5NFYh|ryP MX;TRW5ITVJ?
22RV1 M2PvTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknETWM2OD12Nz65NFE2KM7:TR?= NIHBVVhUSU6JRWK=
G-401 NFTJU|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPWd3dKSzVyPUS4MlQ1OTVizszN MXLTRW5ITVJ?
YAPC Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTR7LkiwO|Mh|ryP MXTTRW5ITVJ?
SW1573 MnPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVq4NJZRUUN3ME21NE4zPDN3IN88US=> M3zqeXNCVkeHUh?=
COLO-792 M3rrfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\EeG96UUN3ME21NE43OjN5IN88US=> M1rPeXNCVkeHUh?=
KNS-62 MmD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XxSWlEPTB;NUCuO|UxQCEQvF2= MV;TRW5ITVJ?
NB5 MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfUO2dKSzVyPUWxMlQ2ODlizszN MUfTRW5ITVJ?
CP66-MEL MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTVzLk[0NFgh|ryP NU\DOWI5W0GQR1XS
CaR-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjZPHJYUUN3ME21Nk4xPjB4IN88US=> MnLiV2FPT0WU
CAL-54 MkPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;PTWM2OD13Mj6xNVAzKM7:TR?= MVzTRW5ITVJ?
8305C M33kcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITGdnJKSzVyPUWyMlMyPSEQvF2= M2PSWnNCVkeHUh?=
Calu-3 Ml;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTV{LkO3N|Mh|ryP Mof2V2FPT0WU
AU565 MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTV{LkW1NFkh|ryP M4DYTXNCVkeHUh?=
CW-2 M2DTNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTV{Lki2OVQh|ryP NH;uWHNUSU6JRWK=
BEN NUnKT3F2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTV|Lke4OlIh|ryP MVHTRW5ITVJ?
NCI-H1975 M{\WdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjnT5BKSzVyPUWzMlg6PjZizszN NV;KeHJUW0GQR1XS
HCT-116 NXXkOVBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfrO4JKSzVyPUW0MlA{OjdizszN Mmm4V2FPT0WU
SH-4 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTV2LkGzPEDPxE1? NVX4bHd3W0GQR1XS
NCI-H1693 M13GZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rwNGlEPTB;NUSuNlExOyEQvF2= NYLpTZpuW0GQR1XS
BPH-1 NXHkfnc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTV3LkK4PVIh|ryP NVXjdlRkW0GQR1XS
CAMA-1 MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTV3LkixNVYh|ryP NVLuZpZDW0GQR1XS
A388 M{f4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIq0TW5KSzVyPUW2MlA6QDVizszN NXfLPI0{W0GQR1XS
C2BBe1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTV4LkK2N|Qh|ryP M2TBeXNCVkeHUh?=
GAMG MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnWc5NKSzVyPUW2MlU6PTVizszN MXrTRW5ITVJ?
MKN28 NVLlcWtqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzWV4dKSzVyPUW2MlgxOTNizszN NYn6S3lyW0GQR1XS
VA-ES-BJ MkHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jSSWlEPTB;NU[uPFc1PSEQvF2= NWm0U3R4W0GQR1XS
HuCCT1 M1rUSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTV5LkC0PVIh|ryP MXvTRW5ITVJ?
BFTC-905 NETIXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTV5LkK4PVgh|ryP M2jxenNCVkeHUh?=
LS-123 NF24UXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTV5LkW2Olgh|ryP NHrSSYtUSU6JRWK=
LB996-RCC M1jrbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYX6Rno6UUN3ME21PE4xOjh5IN88US=> MofPV2FPT0WU
NCI-H1048 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEOzeWJKSzVyPUW4MlIyQDhizszN M3q4T3NCVkeHUh?=
COR-L105 NFHjZXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLBNotGUUN3ME21PE44OzN5IN88US=> NW\rSVZLW0GQR1XS
OVCAR-8 NIPKdIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nNTmlEPTB;NUmuNVcyPiEQvF2= MnvFV2FPT0WU
SK-N-FI M2S2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHq2cWpKSzVyPUW5MlMzODdizszN NVjEXHVEW0GQR1XS
MES-SA MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\1RnVFUUN3ME21PU41PTB7IN88US=> NXfoZmsxW0GQR1XS
SCC-9 M2TtbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELOZ2xKSzVyPUW5MlQ4PTNizszN MljSV2FPT0WU
EFO-27 NGj0SlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTV7Lkm0N{DPxE1? MXTTRW5ITVJ?
GT3TKB Mn\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIH2R5BKSzVyPU[wMlYxPDhizszN M3vwbXNCVkeHUh?=
HCC38 NGjzT3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4W0dmlEPTB;NkGuOFM4QSEQvF2= M1q5Z3NCVkeHUh?=
MLMA NUnReHl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LydWlEPTB;NkGuOlE3OyEQvF2= NUO4Vms5W0GQR1XS
D-566MG MkfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPyT5hEUUN3ME22N{42OjJ2IN88US=> M2DufXNCVkeHUh?=
SF295 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILFbIpKSzVyPU[zMlY3PTVizszN Mlf6V2FPT0WU
ES4 NVm1TppzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTZ2LkS3NVkh|ryP MYHTRW5ITVJ?
CAKI-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTvTWM2OD14ND61O|IyKM7:TR?= NFjCW3NUSU6JRWK=
OAW-28 M1X1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTZ2Lkm2OFch|ryP NWjzfYc5W0GQR1XS
NCI-H460 MofqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1OwTWlEPTB;NkWuNFg6PyEQvF2= MVXTRW5ITVJ?
JAR NXjuVW5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37PSGlEPTB;NkWuOVUyPiEQvF2= MmrLV2FPT0WU
SNU-449 MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXscWFQUUN3ME22OU44PjF4IN88US=> MlXGV2FPT0WU
D-392MG M2G2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M176e2lEPTB;NkWuPVQ{PCEQvF2= M3GxZnNCVkeHUh?=
EW-22 M{nib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nhVWlEPTB;Nk[uN|k2KM7:TR?= M2TrPHNCVkeHUh?=
GCT NYnDbVhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\2c2NKSzVyPU[3MlA1PDNizszN NWfUZYQ2W0GQR1XS
NOS-1 NGDSR2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HMe2lEPTB;NkeuOlg3PyEQvF2= M{XzRXNCVkeHUh?=
RH-1 NUXYelg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;EdXZKSzVyPU[4MlU2PTlizszN MojXV2FPT0WU
HuH-7 NHvS[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlG3TWM2OD14OT6xNFAzKM7:TR?= MXjTRW5ITVJ?
NUGC-3 MnXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTBTWM2OD15MD65OlQ1KM7:TR?= NHj4NJhUSU6JRWK=
IST-SL1 MnLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzmU5VKSzVyPUexMlI{OjRizszN Mnn4V2FPT0WU
SHP-77 NWnJcJN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTd{LkGxPUDPxE1? NH7LVI9USU6JRWK=
SW1116 Ml7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPldolKSzVyPUeyMlE1ODdizszN NXrtTZFJW0GQR1XS
LK-2 NUW2NJBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzxRmhKSzVyPUeyMlg3OTJizszN Mof3V2FPT0WU
U-2-OS MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M362VWlEPTB;N{OuNVgzQCEQvF2= MkLJV2FPT0WU
KYSE-150 NX3WPZlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PzZWlEPTB;N{OuOlEyQCEQvF2= MnHoV2FPT0WU
U251 Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DsNGlEPTB;N{OuPFE3QCEQvF2= MVjTRW5ITVJ?
HT-1080 NGfJToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTd2LkK1O|Qh|ryP NEi3UZNUSU6JRWK=
NCI-H1437 MkP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPUTWM2OD15ND62N|I3KM7:TR?= Moi4V2FPT0WU
HPAF-II NHvxOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrkdY9{UUN3ME23OE43PDF3IN88US=> NHXkVGlUSU6JRWK=
Becker NWXmOop6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTd3LkGxNFUh|ryP MkW2V2FPT0WU
PANC-10-05 MkjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mli0TWM2OD15NT6yPFY2KM7:TR?= M1zLVXNCVkeHUh?=
TYK-nu MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Xnd2lEPTB;N{WuN|ExOiEQvF2= M1n0dnNCVkeHUh?=
SKG-IIIa NY\CTJFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjoTJpKSzVyPUe1MlM{PDFizszN MlnBV2FPT0WU
NCI-H1993 NYrBXJNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX:wOppYUUN3ME23OU44Ozl5IN88US=> NYnnXnB3W0GQR1XS
S-117 NVO1W4dNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILPdnZKSzVyPUe1Mlc2PSEQvF2= MVnTRW5ITVJ?
HuO9 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\RXmYzUUN3ME23Ok4xODR6IN88US=> M4nJVHNCVkeHUh?=
CAL-51 NVvxcWFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvTTWM2OD15Nj6xNFA3KM7:TR?= NH73UZJUSU6JRWK=
BT-20 M{nqXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHwN5d4UUN3ME23Ok4zOTZ6IN88US=> NFPlTW1USU6JRWK=
LB831-BLC M3ro[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPITWM2OD15Nj6zNlE4KM7:TR?= Mn34V2FPT0WU
LB1047-RCC MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;jcWlEPTB;N{[uO|YyQSEQvF2= NYi0OoU1W0GQR1XS
ES8 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{mxSGlEPTB;N{iuNFA4OyEQvF2= MVHTRW5ITVJ?
UMC-11 M1nXSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrYNIJKSzVyPUe4MlA5QDRizszN NUjZem5LW0GQR1XS
NCI-H226 MlPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2T5XmlEPTB;N{iuNVMyPSEQvF2= M2LN[3NCVkeHUh?=
IGROV-1 NWLsO5hrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmizTWM2OD15OD61OVUh|ryP MYnTRW5ITVJ?
BHY NYXEWnN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXKcWNYUUN3ME23PU42QTZizszN NID1TpBUSU6JRWK=
MKN45 NVTVeGozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;RTWM2OD16MD6zNVc1KM7:TR?= NXHRVlVlW0GQR1XS
IA-LM MnGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TNcWlEPTB;OECuN|UyOSEQvF2= NGKxUJFUSU6JRWK=
WM-115 NWDtSldsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPMOWJKSzVyPUixMlQyOTRizszN MlnTV2FPT0WU
VMRC-RCZ M4H6emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vRVmlEPTB;OEGuOFQzPSEQvF2= NWH6WXU6W0GQR1XS
NCI-H2291 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fuRmlEPTB;OEGuOlg1OiEQvF2= NUjMdVJTW0GQR1XS
MCF7 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTh|LkK4PVch|ryP NXOzUoFUW0GQR1XS
639-V NF3wfoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TtcGlEPTB;OESuOlEzQSEQvF2= M{\RV3NCVkeHUh?=
RT4 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\yTWM2OD16NT6yOFA{KM7:TR?= NHvGSIZUSU6JRWK=
NCI-H2405 NXf1OZB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHTTWM2OD16NT6yPVk4KM7:TR?= MlLzV2FPT0WU
CAL-33 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTh3Lk[zNVUh|ryP NILOfFZUSU6JRWK=
BT-549 NH;5U4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTh3LkmzPFIh|ryP MYPTRW5ITVJ?
HT-1197 MmLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXnUGZKSzVyPUi4MlExPzdizszN NH3h[mxUSU6JRWK=
G-361 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTh6LkG0O|Qh|ryP Mlr4V2FPT0WU
LS-411N NWP1c29IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLGZpVnUUN3ME24PU4{Ozh6IN88US=> MXfTRW5ITVJ?
HT-144 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHMb4pRUUN3ME24PU42QTl{IN88US=> NVvMbVlOW0GQR1XS
DJM-1 Mn7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTyc4pDUUN3ME24PU45QDR3IN88US=> M{nSbHNCVkeHUh?=
CAL-12T MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTlyLke4PVUh|ryP M4PTZXNCVkeHUh?=
MKN7 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jmXmlEPTB;OUGuN|U2OSEQvF2= MljjV2FPT0WU
HuP-T3 NH;CeoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;xTWM2OD17Nj6xNFA1KM7:TR?= Ml;yV2FPT0WU
SK-MG-1 MoqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTOSGtKSzVyPUm2MlE{PDhizszN M4PPSnNCVkeHUh?=
NCI-H2347 MorhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzBO|Y5UUN3ME25PE4yODR{IN88US=> MlT5V2FPT0WU
SW872 Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ThPGlEPTB;MUCwMlQ2PiEQvF2= NI[zNoxUSU6JRWK=
COLO-829 MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXkTlFOUUN3ME2xNFAvPTV|IN88US=> MnnKV2FPT0WU
MC-IXC M3;FUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTFyMD62NVUh|ryP Mn\UV2FPT0WU

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
p-mTOR / mTOR / p-p70S6K / p70S6K ; 

PubMed: 30423811     


As determined using Western blotting, the phospho-p70S6K (p-p70S6K) inhibitor (PF-4708671) reduced the expression of phospho-mTOR (p-mTOR) and p-p70S6K in SCC-4 and SCC-25 cells. SCC-4 and SCC-25 cells were not treated as negative control (NC) or treated with 20 µM PF-4708671 for 6 h (6 h), 12 h (12 h), 18 h (18 h), 1 day (1 d), 2 days (2 d), and 3 days (3 d). Western blot analysis was performed to examine the expression levels of p-mTOR, mTOR, p-p70S6K, p70S6K, and β-actin.

pS6 / S6 / pS6K / S6K1 / pAKT / AKT ; 

PubMed: 28626016     


Western blot of cell lysates from neurons treated with PF-4708671, rapamycin, and Torin-2, individually or in combination for the indicated times.

30423811 28626016
Growth inhibition assay
Cell viability; 

PubMed: 30423811     


Inhibitory effects of various doses (0.5, 1, 2, 5, 10, 20, and 40 µM) of PF-4708671 on SCC-4 (B) and SCC-25 (C) cells were assessed using MTT assay after 72 h of treatment. Data presented are the mean and standard error of the mean of three independent experiments. * p < 0.05, ** p < 0.01, and *** p < 0.001 indicate the statistical significance of differences between cells with and without treatment. t (red ** and *** for SCC-4 and blue *, ** and *** for SCC-25).

30423811

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 DMSO 30 mg/mL (76.84 mM)
Ethanol 8 mg/mL (20.49 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
30% PEG400+0.5% Tween80+5% propylene glycol
 30 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 390.41
化学式

C19H21F3N6
CAS号 1255517-76-0
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量 只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1：

    Whether the in vivo formula "30% PEG400+0.5% Tween80+5% Propylene glycol" for S2163 is suitable for i.p. or not?

  • 回答：

    The formula "30% PEG400+0.5% Tween80+5% Propylene glycol" on our website is an oral one. It is a suspension.

Selleck产品目录册

S6 Kinase Signaling Pathway Map

相关S6 Kinase产品

  • LY2584702 New

    LY2584702是一种选择性的，ATP竞争性的p70S6K抑制剂，IC50为4 nM。Phase 1。

  • LY2584702 Tosylate New

    LY2584702 Tosylate是一种选择性的，ATP竞争性p70S6K抑制剂，IC50为 4 nM。Phase 1。

  • CHIR-99021 (CT99021) New

    CHIR-99021 (CT99021)是一种GSK-3α和GSK-3β抑制剂， IC50分别为10 nM and 6.7 nM。CHIR99201对CDKs没有交叉反应性，对GSK-3β的选择性是对CDKs选择性的350倍。CHIR-99021 可作为Wnt/β-catenin的激活剂并诱导自噬。

  • BI-D1870

    BI-D1870是一种ATP-竞争性S6 ribosome抑制剂，在无细胞试验中作用于RSK1/2/3/K4，IC50分别为31 nM/24 nM/18 nM/15 nM，作用于RSK比作用于MST2，GSK-3β，MARK3，CK1和Aurora B选择性高10到100倍。BI-D1870 显示除了抗癌的属性包括活性氧的生成、提高内质网应激反应和诱导自噬。

  • Rapamycin (AY-22989)

    Rapamycin (AY-22989, Rapamune, Sirolimus, NSC-2260804)是一种特定的 mTOR 抑制剂，在 HEK293细胞中，IC50 为 ~0.1 nM。

  • MK-2206 2HCl

    MK-2206 2HCl是一种高度选择性的Akt1/2/3抑制剂，在无细胞试验中IC50分别为8 nM/12 nM/65 nM；对250种其他蛋白激酶没有抑制活性。MK-2206 2HCl 在肿瘤细胞中可诱导自噬和凋亡。Phase 2。

    Features:MK-2206是第一个进入临床研究阶段的Akt小分子变构抑制剂。

  • CHIR-99021 (CT99021) HCl

    CHIR-99021 (CT99021) HCl是CHIR-99021的盐酸盐, 是GSK-3α/β抑制剂，IC50为10 nM/6.7 nM。其对GSK-3的选择性比对Cdc2和ERK2高500倍以上。CHIR-99021 是一种有效的药理性的 Wnt/beta-catenin 信号通路的激活剂。CHIR-99021 可显著地拯救光诱导的 autophagy，并可增强 GR，RORα和自噬相关蛋白等表达。

  • LY294002

    LY294002 (SF 1101, NSC 697286) 是首个合成的已知抑制PI3Kα/δ/β的小分子，在无细胞测定中IC50分别为 0.5 μM/0.57 μM/0.97 μM；在溶液中比在Wortmannin中稳定，也能够阻断自噬体的形成。它不仅能够结合class I PI3Ks和其他PI3K相关的激酶，还能够结合一些与PI3K家族无关的新型靶点。LY294002 可以抑制CK2，对应的IC50值为98 nM。LY294002 是一种非特异的 DNA-PKcs 抑制剂，并可激活自噬和凋亡。

    Features:LY294002是选择性的, 可渗透细胞的特定PI3K抑制剂，可作用于酶的ATP结合位点，且抑制自体吞噬的螯合作用。

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA, NSC 66389) 是一种选择性PI3K抑制剂，作用于Vps34和PI3Kγ，在 HeLa细胞中IC50分别为25 μM和60 μM；永久性抑制I型PI3K，但对III型PI3K的抑制是短暂的，也会阻断自噬体的形成。3-Methyladenine (3-MA)可成功应用于抑制线粒体自噬。现配现用（加热助溶）。

  • Everolimus (RAD001)

    Everolimus (RAD001, SDZ-RAD)是一种mTOR抑制剂，作用于FKBP12，在无细胞试验中IC50为1.6-2.4 nM。Everolimus 可诱导细胞凋亡及自噬并抑制肿瘤细胞的增殖。

Tags: 购买PF-4708671 | PF-4708671供应商 | 采购PF-4708671 | PF-4708671价格 | PF-4708671生产 | 订购PF-4708671 | PF-4708671代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID